SECsense Logo

Purple Biotech Ltd. Unveils Phase 2 Trial for NT219 in Head and Neck Cancer - February 2025 Update

$PPBT
Form 6-K
Filed on: 2025-02-18
Source
Purple Biotech Ltd. Unveils Phase 2 Trial for NT219 in Head and Neck Cancer - February 2025 Update

Here are the key insights extracted from the financial report of Purple Biotech Ltd. (Form 6-K):

  1. Company Information:
  • Name: Purple Biotech Ltd.
  • Address: 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
  • SEC Commission File Number: 001-37643.
  1. Reporting Period:
  • The report is for the month of February 2025.
  1. Press Release Announcement:
  • On February 18, 2025, Purple Biotech announced a significant advancement in its clinical research:
    • The company is advancing NT219 into a Phase 2 trial focused on Head and Neck Cancer.
    • This announcement is crucial for investors and stakeholders as it indicates progress in the company's product pipeline.
  1. Exhibits:
  • The press release regarding the advancement of NT219 is included as Exhibit 99.1.
  1. Incorporation by Reference:
  • This report on Form 6-K includes provisions for incorporation by reference into several previous registration statements filed with the SEC, which may have implications for future capital raising or securities offerings.
  1. Signatory:
  • The report is signed by Gil Efron, the Chief Executive Officer, which confirms the authenticity and approval of the report’s contents.
  1. Filing Status:
  • The registrant indicated that it files annual reports under Form 20-F.

Overall, the report highlights a key development in Purple Biotech's clinical trials, which could impact its market position and investor interest. The advancement into Phase 2 trials is a critical step indicating potential future revenue streams and product viability.